Comprehensive Heart Package
- Total cholesterol
- Triglycerides
- HDL
- LDL
- Non-HDL cholesterol
- Apolipoprotein B (ApoB)
- Apolipoprotein A-I (ApoA-I)
- ApoB/ApoA-I ratio
- Lipoprotein(a) [Lp(a)]
- High-sensitivity CRP (hs-CRP)
- Homocysteine
- CardioNext® hereditary cardiovascular predisposition panel
- CardioScreen® hereditary cardiomyopathy panel
- CardioScreen® panel for hereditary conditions associated with sudden cardiac arrest
- Targeted tests for hereditary heart rhythm disorders
Which tests can be performed to assess cardiovascular health?
Cardiovascular disease risk cannot be determined by a single blood test. Age, blood pressure, smoking, diabetes, kidney disease, family history and previous cardiovascular events are assessed together. Not everyone needs all the tests listed on this page; the physician decides which tests are appropriate based on the individual's medical history and risk level.
The values below are for general information only. LDL-cholesterol and ApoB targets, in particular, vary according to the individual's overall risk; a laboratory reference range and a treatment target are not the same thing. The 2026 ACC/AHA dyslipidemia guideline redefines LDL-C and non-HDL-C targets according to risk level.
Cholesterol and cardiovascular risk tests
| Test | What does it tell us? | In whom or when may it be assessed? | Guideline threshold or target |
|---|---|---|---|
| Total cholesterol | Shows the total amount of cholesterol in the blood. On its own, it does not explain which cholesterol particles are elevated. | It is usually measured together with other lipid tests during the initial lipid assessment and follow-up. | It is not a standalone target for classifying cardiovascular risk or determining treatment. It is interpreted alongside LDL-C, HDL-C, triglycerides and non-HDL-C. |
| LDL cholesterol (LDL-C) | Measures cholesterol that contributes to plaque formation in artery walls. | It is a key test for overall risk assessment, suspected familial hypercholesterolaemia and monitoring cholesterol treatment. | In the 2026 ACC/AHA guideline, treatment targets are determined by risk level: generally <100 mg/dL for borderline/intermediate-risk individuals starting treatment, <70 mg/dL for those at high risk, and <55 mg/dL for those with very-high-risk cardiovascular disease. Targets are determined by the physician according to the clinical situation. |
| HDL cholesterol (HDL-C) | Provides information about one of the forms in which cholesterol is carried in the blood. A high HDL level alone does not protect a person against heart disease. | It is part of the standard lipid profile and is assessed alongside other risk factors. | There is no single HDL target value used in drug treatment. Low HDL may be taken into account in overall risk assessment; treatment aimed solely at raising HDL is not recommended. |
| Triglycerides (TG) | These are another type of fat carried in the blood. Elevated levels may be associated with metabolic and cardiovascular risks. | They are particularly assessed in people with diabetes, excess weight, metabolic syndrome, alcohol use or a history of high triglycerides. | Persistently elevated levels of ≥150 mg/dL when fasting or ≥175 mg/dL when measured without fasting may be taken into account in risk assessment. Very high values are also assessed by a physician for the risk of pancreatitis. |
| Non-HDL cholesterol | Calculated by subtracting HDL from total cholesterol; it reflects the total cholesterol carried in particles associated with atherosclerosis, including LDL. | It may help with interpreting the lipid profile, particularly in cases of elevated triglycerides, diabetes or metabolic risks. | Treatment targets in the 2026 ACC/AHA guideline are determined according to risk level alongside LDL targets: approximately <130 mg/dL, <100 mg/dL or <85 mg/dL. |
| Apolipoprotein B (ApoB) | Provides information about the number of particles that can contribute to atherosclerosis. It may provide additional information when LDL-C and particle number may be discordant. | It may be considered particularly in cases of elevated triglycerides, type 2 diabetes, cardiovascular-kidney-metabolic disease, known vascular disease, or when assessing residual risk after the LDL-C target has been reached. | The guideline recommends assessing ApoB in addition to LDL-C and non-HDL-C in selected individuals. The 2026 ACC/AHA target table includes targets of <90 mg/dL and <70 mg/dL depending on the clinical situation, and <55 mg/dL in some very-high-risk patients. These are not general reference ranges applicable to everyone. |
| Apolipoprotein A-I (ApoA-I) | It is the main protein in HDL particles. | A physician may request ApoA-I together with other tests in specific conditions affecting lipid metabolism. | Major guidelines do not recommend a standard threshold for its use alone in cardiovascular risk screening or as a treatment target. |
| ApoB/ApoA-I ratio | Shows the ratio of atherosclerosis-associated ApoB particles to ApoA-I. | It may be assessed for additional information in selected situations. | There is no common diagnostic or treatment threshold for this ratio used by all guidelines; it does not replace standard lipid tests and clinical risk assessment. |
| Lipoprotein(a) [Lp(a)] | It is an LDL-like particle that is largely inherited. Elevated levels may increase the risk of cardiovascular disease and calcific aortic valve disease. | Measurement at least once in adulthood is recommended. It may be particularly relevant in people who have had cardiovascular disease at a young age, or who have a family history of early heart disease or high Lp(a). | The 2026 ACC/AHA guideline recommends measurement at least once in adulthood. ≥50 mg/dL or ≥125 nmol/L is considered a high-risk marker. The ESC/EAS 2025 update specifies a threshold of >50 mg/dL or >105 nmol/L. Results are assessed according to the method and unit used; a fixed conversion between mg/dL and nmol/L should not be used. |
| High-sensitivity CRP (hs-CRP) | Provides information about low-grade systemic inflammation; it does not diagnose infection or heart disease on its own. | It may be considered in individuals whose conventional risk estimate is borderline, if additional risk information could influence the treatment decision. Results may be misleading in the presence of an active infection or other inflammation. | According to the 2026 ACC/AHA guideline, in suitable individuals with borderline 10-year risk, an hs-CRP level of ≥2 mg/L on two separate measurements, with no other cause for the elevation, may influence risk assessment. |
| Homocysteine | It is a substance produced during amino acid metabolism. Elevated levels may be associated with B12/folate deficiency, kidney disease and certain rare metabolic conditions. | It is generally not recommended for routine cardiovascular risk screening. A physician may consider it if specific metabolic diseases or clinical suspicion are present. | There is no standard target value recommended by guidelines for assessing the risk of heart disease. There is no evidence that lowering homocysteine with vitamins reduces the risk of heart attack and death. |
Cardiac genetic tests available at Wellcare
Unlike cholesterol measurements, genetic tests do not provide a “high/low” blood value. Findings are generally classified as pathogenic, likely pathogenic, of uncertain significance (VUS) or benign, and are interpreted alongside symptoms, ECG/imaging findings and family history. Genetic evaluation may be considered when inherited cardiomyopathy or a heart rhythm disorder is suspected; targeted testing of family members is usually planned after a disease-associated pathogenic/likely pathogenic variant has been identified in the family.
| Test group at Wellcare | What does it investigate? | Who may be considered for testing? | How are reference values or results interpreted? |
|---|---|---|---|
| CardioNext® cardiovascular predisposition panel | Described as a panel of 50 SNPs associated with 54 genes; it examines variants associated with processes such as lipid metabolism, blood pressure and blood clotting. | May be considered for individuals selected by a physician, with results assessed alongside their clinical and family history. | There is no numerical reference range. The common variants in this panel do not, on their own, diagnose heart disease or indicate that a person will develop it. It is not a standard test recommended by guidelines for general population screening. |
| CardioScreen® cardiomyopathy panel | Examines 46 genes associated with heart muscle diseases. | May be considered following specialist assessment in individuals with diagnosed/suspected cardiomyopathy or a family history of inherited cardiomyopathy. | The result is assessed alongside the clinical diagnosis and family history. The most meaningful findings for family screening are generally pathogenic/likely pathogenic variants. |
| CardioScreen® panel for inherited conditions associated with sudden cardiac arrest | A panel of 166 genes associated with inherited heart rhythm disorders and heart muscle diseases. | May be considered following specialist assessment in cases of unexplained cardiac arrest, suspected specific inherited heart rhythm disorders, or families with unexplained sudden death at a young age. | There is no numerical reference value. Genetic testing complements ECG, imaging and clinical assessment; it does not replace them. |
| Targeted tests for inherited heart rhythm disorders | Testing is available for long QT, Brugada, short QT, Jervell–Lange-Nielsen, Andersen–Tawil and Timothy syndromes, cardiac conduction disorders, CPVT and various arrhythmia panels. | May be selected by a cardiologist and a genetics specialist if clinical findings suggest a specific inherited heart rhythm disorder. | The result is interpreted according to the clinical classification of the variant for the relevant condition and gene; a VUS alone does not establish a diagnosis or determine a decision to screen family members. |
Important: Identifying a genetic predisposition does not mean that the disease will definitely develop; a negative result does not rule out all heart diseases either. The decision to undergo genetic testing should be made with clinical specialist assessment and, where possible, genetic counselling before and after testing.
How are results assessed?
Lipid profile, ApoB, Lp(a) and hs-CRP results are interpreted alongside blood pressure, diabetes, smoking, kidney health, family history and existing medical conditions. For example, the same LDL-C result may not indicate the same treatment target for someone who has had a heart attack and someone with no other risk factors. Since Lp(a) usually remains relatively stable throughout life, a single measurement is generally sufficient; however, certain clinical conditions may affect its level.
If symptoms such as chest pain, shortness of breath, fainting or palpitations are present, the risk tests on this page alone are not sufficient. A healthcare professional should be consulted without delay; the necessary cardiac examinations and tests should be planned by a physician.
